within Pharmacolibrary.Drugs.ATC.B;

model B01AC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 8.333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ticlopidine is an oral antiplatelet agent formerly used for the prevention of thrombotic stroke and to reduce the risk of heart attack and other cardiovascular events, particularly in patients intolerant to aspirin. Its use is limited today due to adverse effects such as neutropenia and replaced by newer alternatives like clopidogrel.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, mixed sex, single oral dose.</p><h4>References</h4><ol><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2022.2121702&quot;>10.1080/17512433.2022.2121702</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36065676/&quot;>https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li><li><p>Swainston Harrison, T, &amp; Plosker, GL (2007). Limaprost. <i>Drugs</i> 67(1) 109–120. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200767010-00010&quot;>10.2165/00003495-200767010-00010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17209669/&quot;>https://pubmed.ncbi.nlm.nih.gov/17209669</a></p></li><li><p>Knudsen, JB, et al., &amp; Dickinson, JP (1992). Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 22(5) 579–589. DOI:<a href=&quot;https://doi.org/10.3109/00498259209053121&quot;>10.3109/00498259209053121</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1413873/&quot;>https://pubmed.ncbi.nlm.nih.gov/1413873</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC05;
